India · Investor

Lilly Ventures

Last cheque observed Jan 2017. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

Email

QuietGrowth equity

Series CSeries ASeries BVenture Capital & Private Equity

Cheques on record
0%of best year0cheques in 12 months, 24 on record
Since the last cheque3586days00hrs00min00sec
Median round$26MRounds led0 of 24Sole investor2 roundsExits4 from the portfolioMostly inUnited States, 100%
Pitch Lilly Ventures

Another investor of this name exists, and we could not establish from the rounds which of them the press meant. Treat the record below as possibly belonging to either. Tell us which if you know.

Lilly Ventures highlights

  1. 01

    24 rounds on record

  2. 02

    Mostly Series C and Series A: 61% of its rounds

  3. 03

    Sole investor in 2 rounds, median $20M

  4. 04

    4 exits from the portfolio

What they do

Type
Growth equity (from a list, unverified)
Cheque size
Not stated
Sectors
Venture Capital & Private Equity
Based in
Faridabad, India
Cold pitches
Not stated

The record

Every round we can evidence, newest first24 appearances

  1. 2017

    1 round

  2. Jan
    CavionUS · Vcaonline$26MWith 1 other
  3. 2015

    6 rounds

  4. Dec
    Symic BiomedicalSeries A · US$25MSole investor
  5. Mar
    Aeglea BioTherapeuticsSeries B · US$44MWith 4 others
  6. Mar
    Nimbus TherapeuticsSeries B · US$43MWith 5 others
  7. Feb
    Lysosomal TherapeuticsSeries A · US$20MWith 6 others
  8. Jan
    Surface OncologySeries A · US$35MWith 3 others
  9. Jan
    Symic BiomedicalSeries A · US$15MSole investor
  10. 2014

    6 rounds

  11. Oct
    Aileron TherapeuticsSeries E · US$33MWith 6 others
  12. Oct
    Viamet PharmaceuticalsSeries D · US$60MWith 4 others
  13. Jun
    NumerateSeries C · US$8.2MWith 1 other
  14. May
    Coherus BiosciencesSeries C · US$55MWith 9 others
  15. May
    Lysosomal TherapeuticsSeed · US$4.8MWith 6 others
  16. Jan
    Aeglea BioTherapeuticsSeries A · US$12MWith 5 others
  17. 2008

    1 round

  18. Mar
    Hydra BiosciencesSeries C · US$34MWith 5 others
  19. 2007

    4 rounds

  20. Nov
    HemaQuest PharmaceuticalsSeries A · US$20MWith 2 others
  21. Aug
    MedManage SystemsSeries E · US$5.0MWith 3 others
  22. Jun
    SerenexSeries D · US$26MWith 9 others
  23. Jan
    FluidigmSeries E · US$37MWith 7 others
  24. 2005

    2 rounds

  25. Dec
    GlobeImmuneSeries B · US$34MWith 7 others
  26. Oct
    SerenexSeries C · US$30MWith 5 others
  27. 2004

    3 rounds

  28. Sept
    Remon Medical TechnologiesSeries C$16MWith 4 others
  29. Apr
    MedManage SystemsSeries C · US$6.0MWith 2 others
  30. Jan
    CGI PharmaceuticalsSeries C · US$22MWith 6 others
  31. 2002

    1 round

  32. Nov
    NexCuraSeries C · US$4.0MWith 2 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

Exits from the portfolio

Companies it backed that were later bought or listed4 in all

CGI PharmaceuticalsBought by Gilead Sciences$120MJun 2010
MedManage SystemsBought by Physicians InteractiveUndisclosedApr 2009
SerenexBought by PfizerUndisclosedMar 2008
NexCuraBought by The Thompson CorporationUndisclosedNov 2005

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Lilly Ventures. A count of rooms they were both in, not a relationship either has claimed.

Atlas VentureVC firm5rounds togetherNovartis Venture FundCorporate VC4rounds togetherHatteras Venture PartnersVC firm3rounds togetherIntersouth PartnersVC firm3rounds togetherRoche Venture FundCorporate VC3rounds togetherVersant VenturesVC firm3rounds togetherF-Prime CapitalVC firm2rounds togetherMediphase Venture PartnersVC firm2rounds togetherNew Enterprise AssociatesVC firm2rounds togetherPartners HealthCare InnovationCorporate VC2rounds togetherPolaris PartnersVC firm2rounds togetherRitchie Capital ManagementVC firm2rounds together

Recently backed

The latest companies Lilly Ventures put money into.

Cavion$26M · Jan 2017

Quick answers about Lilly Ventures

What does Lilly Ventures invest in?

Lilly Ventures invests most often at Series C and Series A (61% of the rounds on record), in sectors such as Venture Capital & Private Equity.

How active is Lilly Ventures?

24 investments on record, 0 of them in the last 12 months. The most recent was in Jan 2017.

What has Lilly Ventures invested in recently?

Its most recent investments on record: Cavion (Undisclosed round, Jan 2017).

How big are Lilly Ventures's cheques?

The median round it joins is $26M.

Does Lilly Ventures lead rounds?

Rarely, if at all: none of its 24 investments on record names it as the lead.

Where does Lilly Ventures invest?

Most of the companies it backs are in the United States (100%).

Is Lilly Ventures investing now?

No investments in the last 12 months; the latest was in Jan 2017.

Who does Lilly Ventures invest alongside?

Most often Atlas Venture (5 rounds together), Novartis Venture Fund (4 rounds together) and Hatteras Venture Partners (3 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it